GENE ONLINE|News &
Opinion
Blog

2021-06-18| ChinaPolicySpecial

From Great Challenges to Great Opportunities: An Outlook on US-China Biotech Relationships

by Daniel Ojeda
Share To
The US-China relationship is under a lot of stress following a trade war and a global pandemic. For companies, these are crucial markets that offer great opportunities but also great challenges.
During the BIO Digital 2021, a panel of policy experts discussed their opinions and views on how the US-China relationships will affect biotechnology companies in 2021. 

GO Prime with only $1.49 now

LATEST
35% Of Better Therapeutics’ Staff to be Cut to Extend the Company’s Runway
2023-03-27
Pharming’s Joenja Racks Up FDA Approval For Rare Primary Immunodeficiency
2023-03-27
Ways to Reduce Carbon Emission in Cement Manufacturing
2023-03-26
Moderna Injects $76 Million To Kickstart Lipid Nanoparticle Delivery Partnership With Generation Bio
2023-03-24
Shining a Light on Oncology with Rakuten Medical Co-CEO Takashi Toraishi
2023-03-23
Incyte’s Zynyz Secures FDA Approval for Treating a Rare and Aggressive Skin Cancer
2023-03-23
Biohaven Licenses TYK2/JAK1 Dual Inhibitor From China’s Highlight In $970 Million Pact
2023-03-23
Scroll to Top